Top-line Results From MaGic, a Phase Two Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis (S14.007)

Stojan Peric; Puspha Narayanaswami; Marek Śmilowski; Agnieszka Słowik; Sankalp Gokhale; Caitlin Briggs; Uzma Siddiqui; Simrat Randhawa; Matt Truman; Luke Hickey; Shahar Shelly; Tuan Vu; John Vissing

doi:10.1212/wnl.0000000000216763

June 9, 2026Neurology

Top-line Results From MaGic, a Phase Two Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis (S14.007)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the safety and effectiveness of claseprubart for treating adults with AChR Ab+ generalized Myasthenia Gravis.
Phase two randomized trial
Participants were adults with acetylcholine receptor antibody positive generalized Myasthenia Gravis.
Evaluated safety and efficacy of claseprubart compared to standard treatments.
Claseprubart showed significant improvement in muscle strength for AChR Ab+ patients with generalized Myasthenia Gravis.
Significant reduction in Myasthenia Gravis symptoms as measured by clinical assessments.
Safety profile indicates tolerable side effects without severe adverse events.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase two trial assesses efficacy and safety of claseprubart in AChR Ab+ generalized Myasthenia Gravis, suggesting potential benefits.

Abstract

To assess the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive (AChR Ab+) generalized Myasthenia Gravis (gMG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peric et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f05663b https://doi.org/10.1212/wnl.0000000000216763

View at Publisher

Ask AI

Bookmark

Share

Top-line Results From MaGic, a Phase Two Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis (S14.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Top-line Results From MaGic, a Phase Two Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis (S14.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading